<DOC>
	<DOCNO>NCT00928174</DOCNO>
	<brief_summary>The purpose study determine whether positron emission tomography / compute tomography ( PET/CT ) use fluorine-18 fluorocholine image agent characterize regional response anti-androgen therapy manner future aid customize planning treatment patient androgen-insensitive prostate cancer .</brief_summary>
	<brief_title>Measurement Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT Androgen-Insensitive Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<mesh_term>Fluorides</mesh_term>
	<criteria>1 . Provision write informed consent . 2 . Men , 18 year age , histologicallyconfirmed diagnosis prostate cancer 3 . History treatment complete androgen blockade great 3 month prior enrollment 4 . Serum testosterone level &lt; 50 ng/ml . Castrate testosterone level must orchiectomy current therapy leutinizing hormonereleasing hormone agonist . 5 . Progressive disease evidence two consecutive rise prostate specific antigen ( PSA ) nadir value , absolute value late PSA &gt; 2 . 0 ng/ml . 6 . Patient undergoing therapeutic intervention supervision treat physician ( urologist , oncologist ) . 1 . Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma superficial transitional cell carcinoma bladder . 2 . Serious underlie medical condition would otherwise impair patient 's ability undergo imaging . 3 . Patient weigh 350 lb ( due scanner weight limit ) . 4 . Clinical life expectancy &lt; 12 week . 5 . Participated radioactive drug study estimate total cumulative dose within 1 year &gt; 0.05 Sievert whole body , active bloodforming organ , eye lens , gonad , 0.15 Sievert organ . 6 . Concurrent Therapy . Allowed : prior hormonal therapy ; concurrent leuteinizing hormone release hormone ( LHRH ) agonist ; prior surgery ; prior concurrent bisphosphonate . Not allow : concurrent antiandrogen secondary hormonal therapy , prior concurrent chemotherapy , concurrent radiotherapy radioisotope therapy ( e.g. , strontium ) . Other : Prior radiotherapy radioisotope therapy must &gt; 12 week since last treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Androgen insensitive prostate cancer</keyword>
</DOC>